Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etelcalcetide

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

Eisai takes control of weight loss drug Belviq from Arena

Buys global rights to obesity drug in $49m deal to expedite roll-out and boost sales

Sanofi reception

Sanofi launches insulin combo Soliqua in US

Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Novartis day

Novartis buys two firms in pre-Christmas shopping spree

Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma

Choose or lose

The divergence of business models demands brave choices

- PMLiVE

FDA okays Clovis’ Lynparza rival rucaparib

Analysts predict Rubraca could become a $1.5bn-plus product by 2020

- PMLiVE

Making a list and checking it twice…

The promise of mobile health lies not in recording information but in promoting behaviour change

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links